Researchers with City of Hope ®, one of the largest and most advanced cancer research and treatment organizations in the U.S. with its National Medical Center named top 5 in the nation for cancer by U ...

Two of Gilead Sciences' most important drugs missed sales expectations late Thursday. Gilead stock fell early Friday.

MemorialCare Saddleback Medical Center has launched a new Skin Cancer Program and specialized Melanoma Clinic to provide ...

Linda Jackson, who is living with stage 4 metastatic cancer, is running this year's London Marathon alongside her son David ...

Gilead Sciences' Q1 2025 earnings reveal challenges in oncology and Veklury sales, while HIV therapies remain strong. See why ...

The company's first-quarter revenue slipped 0.3% year-over-year to $6.67 billion, while analysts surveyed by Visible Alpha ...

Once considered a disease of older adults, colorectal cancer is now on the rise among young people in at least 27 countries.

In 2022, infections were linked to 2.5 million new cancer diagnoses. The primary bacterium involved in carcinogenic ...

Abstract: Liver cancer remains one of the main causes of mortality worldwide, requiring advancements in diagnostic systems for early detection and improved patient outcomes. Computed tomography (CT) ...

Removing EPO signaling in mouse liver tumors leads to tumor regression along with sensitivity to immunotherapy.

Removing EPO signaling in mouse liver tumors leads to tumor regression along with sensitivity to immunotherapy.

Gilead Sciences, Inc. ( NASDAQ: GILD) Q1 2025 Earnings Conference Call April 24, 2025 4:30 PM ET Jacquie Ross - SVP, Treasury & IR Daniel O'Day - Chairman, CEO Johanna Mercier - Chief Commercial ...